|
|
Vaccine Detail
|
Von Hippel-Lindau Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Von Hippel-Lindau Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007180
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: VHL
- VHL
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Description: This is for Renal Cancer (NCT00001703). A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein (NCI04) (Rahma et al., 2010; NCIT_C2492).
|
| Host Response |
|
|
| References |
NCIT_C2492: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2492]
NCT00001703: [https://clinicaltrials.gov/show/NCT00001703/]
Rahma et al., 2010: Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. Journal of translational medicine. 2010; 8; 8. [PubMed: 20109232].
|
|
